Sacituzumab Govitecan for Triple-Negative Breast Cancer: Aditya Bardia, MD

Recently, the FDA granted regular approval to sacituzumab govitecan (Trodelvy®, Immunomedics, Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously been treated with two or more systemic therapies, at least one of them for metastatic disease. The FDA had previously granted accelerated approval to sacituzumab govitecan based on the results of the phase 1/2 IMMU-132-01 study (NCT01631552); the phase 3 ASCENT study (NCT02574455)...
Continue reading

Sacituzumab Govitecan Granted Regular Approval for Triple-Negative Breast Cancer

The FDA has granted regular approval to sacituzumab govitecan (Trodelvy®, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who previously have been treated with two or more systemic therapies, at least one of them for metastatic disease. Previously, the FDA had granted accelerated approval to sacituzumab govitecan based on the results of the phase 1/2 IMMU-132-01 study (NCT01631552); the ASCENT study (NCT0257445...
Continue reading

Does Adjuvant Chemotherapy Benefit Small, Node-Negative TNBC?

Researchers set out to investigate the association between adjuvant chemotherapy and outcomes in patients with small, node-negative, triple-negative breast cancer (TNBC) and found that whereas adjuvant chemotherapy was associated with increased overall survival (OS) in older patients with pT1b tumors, younger patients with pT1a tumors experienced higher rates of mortality. For this observational study, results of which are published in JAMA Oncology, 16,180 patients from the National Cancer Data...
Continue reading

Immunotherapy in Triple-Negative Breast Cancer: An Interview With Leisha Emens, MD, PhD

​The FDA's approval of atezolizumab (Tecentriq®, Genentech, Inc.) in combination with nab-paclitaxel for patients with previously untreated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) expressing programmed death-ligand 1 (PD-L1) represents the first approval of an immune checkpoint inhibitor for breast cancer. In addition, it is an important development for patients with TNBC, which lacks many of the targeted therapies that can be used in other types of breas...
Continue reading

First Checkpoint Immunotherapy Approved in Breast Cancer

The FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.) in combination with nab-paclitaxel as a first-line treatment for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express programmed death-ligand 1 (PD-L1). This is the first FDA approval of an immune checkpoint inhibitor for any type of breast cancer. It is also a substantial development for patients with TNBC, a highly aggressive subtype that lacks many of the targeted the...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.